Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02537303 | FINLIUS | JANSSEN INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02537311 | FINLIUS I.V. | JANSSEN INC | Solution | USTEKINUMAB 5 MG | Marketed |
| 02564904 | IMULDOSA | ACCORD HEALTHCARE INC | Solution | USTEKINUMAB 90 MG | Approved |
| 02564890 | IMULDOSA | ACCORD HEALTHCARE INC | Solution | USTEKINUMAB 45 MG | Approved |
| 02564882 | IMULDOSA IV | ACCORD HEALTHCARE INC | Solution | USTEKINUMAB 5 MG | Approved |
| 02543036 | JAMTEKI | JAMP PHARMA CORPORATION | Solution | USTEKINUMAB 45 MG | Marketed |
| 02543044 | JAMTEKI | JAMP PHARMA CORPORATION | Solution | USTEKINUMAB 90 MG | Marketed |
| 02553120 | JAMTEKI I.V. | JAMP PHARMA CORPORATION | Solution | USTEKINUMAB 5 MG | Marketed |
| 02554291 | OTULFI | FRESENIUS KABI CANADA LTD | Solution | USTEKINUMAB 90 MG | Marketed |
| 02554283 | OTULFI | FRESENIUS KABI CANADA LTD | Solution | USTEKINUMAB 45 MG | Marketed |
| 02565420 | OTULFI | FRESENIUS KABI CANADA LTD | Solution | USTEKINUMAB 45 MG | Approved |
| 02554305 | OTULFI I.V. | FRESENIUS KABI CANADA LTD | Solution | USTEKINUMAB 5 MG | Marketed |
| 02562987 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 45 MG | Approved |
| 02562995 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 45 MG | Approved |
| 02550547 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 90 MG | Marketed |
| 02563002 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 90 MG | Approved |
| 02550539 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 45 MG | Marketed |
| 02550520 | PYZCHIVA I.V. | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 5 MG | Marketed |
| 02320673 | STELARA | JANSSEN INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02320681 | STELARA | JANSSEN INC | Solution | USTEKINUMAB 90 MG | Marketed |
| 02459671 | STELARA I.V. | JANSSEN INC | Solution | USTEKINUMAB 5 MG | Marketed |
| 02558270 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 45 MG | Approved |
| 02550245 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 45 MG | Marketed |
| 02566532 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 45 MG | Approved |
| 02566540 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 90 MG | Approved |
| 02550253 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 90 MG | Marketed |
| 02550261 | STEQEYMA IV | CELLTRION INC. | Solution | USTEKINUMAB 5 MG | Marketed |
| 02553317 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02553309 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 90 MG | Marketed |
| 02544199 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 90 MG | Marketed |
| 02544180 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02544202 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02544210 | WEZLANA I.V. | AMGEN CANADA INC | Solution | USTEKINUMAB 5 MG | Marketed |
| 02562103 | YESINTEK | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 90 MG | Marketed |
| 02566478 | YESINTEK | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 45 MG | Approved |
| 02569841 | YESINTEK | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 90 MG | Approved |
| 02562081 | YESINTEK | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02569833 | YESINTEK | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 45 MG | Approved |
| 02562111 | YESINTEK I.V. | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 5 MG | Marketed |